Featured Research

from universities, journals, and other organizations

Dosage of HIV drug may be ineffective for half of African-Americans

Date:
August 27, 2014
Source:
Johns Hopkins Medicine
Summary:
Many African-Americans may not be getting effective doses of the HIV drug maraviroc because they are more likely than European-Americans to inherit functional copies of a protein that speeds the removal of the drug from the body.

Many African-Americans may not be getting effective doses of the HIV drug maraviroc, a new study from Johns Hopkins suggests. The initial dosing studies, completed before the drug was licensed in 2007, included mostly European-Americans, who generally lack a protein that is key to removing maraviroc from the body. The current study shows that people with maximum levels of the protein -- including nearly half of African-Americans -- end up with less maraviroc in their bodies compared to those who lack the protein even when given the same dose. A simple genetic test for the gene that makes the CYP3A5 protein could be used to determine what doses would achieve effective levels in individuals, the researchers say.

Related Articles


The results of the small study were published online on Aug. 12 in the journal Drug Metabolism and Disposition.

"Because African-Americans are disproportionately affected by HIV infection, it is doubly important that we get the dosing right," says Namandje Bumpus, Ph.D., an assistant professor of pharmacology and molecular sciences at the Johns Hopkins University School of Medicine.

CYP3A5 is a protein found in abundance in liver and intestinal cells. It adds an oxygen molecule to various drugs to make them more water-soluble so they can ultimately enter the urine and leave the body. Eighty to 90 percent of European-Americans have no CYP3A5, because they have inherited two dysfunctional copies of the CYP3A5 gene.

Normally, the absence of CYP3A5 is not noticeable; a very similar protein, CYP3A4, acts on most of the same drugs. But, for a few drugs, like maraviroc and the cancer drug vincristine, CYP3A5 seems to play a particularly prominent role in helping to remove them from the body. In those cases, the presence or absence of CYP3A5 would likely affect the amount of a drug in the bloodstream, the Johns Hopkins team predicted. And since 85 percent of participants in the maraviroc dosing study were European-Americans, who typically lack functional CYP3A5, the researchers surmised that the recommended dose for maraviroc could be too low for anyone with two functional copies of the gene -- including 45 percent of African-Americans.

To test this idea, the research team grouped 24 healthy volunteers according to how many functional copies of the CYP3A5 gene they had -- zero, one or two. They were each given a single dose of maraviroc in the recommended dose of 300 milligrams, and each participant's blood was taken at 10 time points over 32 hours.

At almost all time points, the concentrations of maraviroc were similar for the groups with zero or one functioning copies of CYP3A5 but were lower in those with two functioning copies. Compared to those with two poorly functioning copies of the gene, those with two functioning copies had a 41 percent lower concentration overall. Importantly, as a group, those with two functioning copies had an average concentration that was just above the lowest level determined to be effective against the virus. And four of the eight had individual average concentrations that dropped below that.

"The trend we saw was that the more functional CYP3A5 a person had, the faster maraviroc was processed and left the body, so the lower its concentration in the bloodstream," explains Bumpus. "What's nice is that, if a larger study confirms that we are underdosing this group, a simple genetic test prior to dosing decisions could rectify the situation."

She adds that this study highlights the importance of designing clinical trials in which the participants are as ethnically diverse as the population to be treated.


Story Source:

The above story is based on materials provided by Johns Hopkins Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. Y. Lu, E. J. Fuchs, C. W. Hendrix, N. N. Bumpus. Cytochrome P450 3A5 Genotype Impacts Maraviroc Concentrations in Healthy Volunteers. Drug Metabolism and Disposition, 2014; DOI: 10.1124/dmd.114.060194

Cite This Page:

Johns Hopkins Medicine. "Dosage of HIV drug may be ineffective for half of African-Americans." ScienceDaily. ScienceDaily, 27 August 2014. <www.sciencedaily.com/releases/2014/08/140827141406.htm>.
Johns Hopkins Medicine. (2014, August 27). Dosage of HIV drug may be ineffective for half of African-Americans. ScienceDaily. Retrieved December 21, 2014 from www.sciencedaily.com/releases/2014/08/140827141406.htm
Johns Hopkins Medicine. "Dosage of HIV drug may be ineffective for half of African-Americans." ScienceDaily. www.sciencedaily.com/releases/2014/08/140827141406.htm (accessed December 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, December 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins